Researchers boost immune 'killer cells,' increase antibody effectiveness against cancer

Apr 18, 2007

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body. They have found that adding such cells to anti-cancer therapies involving monoclonal antibody drugs is more effective in killing cancer cells, and perhaps someday may improve treatments.

Reporting April 18, 2007 at the annual meeting of the American Association for Cancer Research in Los Angeles, scientists led by Takami Sato, M.D., K. Hasumi Associate Professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University showed in laboratory studies that adding such NK cells to a monoclonal antibody, Herceptin, which targets the HER2/neu protein on breast cancer cells, was more efficient at killing the cancer cells. The HER2/neu protein is expressed in approximately one-quarter of all breast cancers.

According to Dr. Sato, monoclonal antibodies help kill cancer cells by attaching to the cancer cell surface, in turn stimulating an outpouring of "effector" cells such as NK cells that attempt to neutralize the cancer. NK cells alone are often powerful cancer fighters, he notes, but NK cell function in cancer patients can be diminished, and chemotherapy can make things even worse.

Dr. Sato, international research study coordinator Mizue Terai, M.S., and their co-workers decided to try a different approach. They cultured peripheral blood mononuclear cells, which are a mixture of immune cells, including NK cells, for three weeks in the test tube with their novel technique. The resulting population of NK cells increased 500 to 1,000-fold. In subsequent experiments, they showed that the combination of NK cells and Herceptin was effective in killing HER2/neu-expressing breast cancer cells, though the effect depended on the amount of antibody.

They found that the expanded group of NK cells and antibody had little effect against breast cancer cells that did not express the HER2/neu protein.

"It [the results] doesn’t mean that the antibody and the NK cells will cure the cancer," Dr. Sato notes, "but it shows that using an antibody that recognizes the cancer cell along with added NK cells can be very effective against the tumor."

The researchers also found that the monoclonal antibody Rituxan greatly enhanced the cancer cell-killing ability of the expanded NK cells against another cancer cell line, B-cell lymphoma cell line. Rituxan is typically used in combination with chemotherapy to treat patients with B-cell non-Hodgkin’s lymphoma.

Dr. Sato says that the technique can be applied to "any cancer that has a monoclonal antibody available."

The team’s next step is to test the effectiveness of the added NK cells in an animal model. The group is also in the process of starting an early phase clinical study.

Source: Thomas Jefferson University

Explore further: Study shows epigenetic changes can drive cancer

add to favorites email to friend print save as pdf

Related Stories

The birth of topological spintronics

13 minutes ago

The discovery of a new material combination that could lead to a more efficient approach to computer memory and logic will be described in the journal Nature on July 24, 2014. The research, led by Penn S ...

Student develops filter for clean water around the world

41 minutes ago

Roughly 780 million people around the world have no access to clean drinking water. According to the World Health Organization (WHO), 3.4 million people die from water-related diseases every year. ETH student Jeremy Nussbaumer ...

How much magma is hiding beneath our feet?

43 minutes ago

Molten rock (or magma) has a strong influence on our planet and its inhabitants, causing destructive volcanic eruptions and generating some of the giant mineral deposits. Our understanding of these phenomena ...

Recommended for you

Study shows epigenetic changes can drive cancer

Jul 26, 2014

Cancer has long been thought to be primarily a genetic disease, but in recent decades scientists have come to believe that epigenetic changes – which don't change the DNA sequence but how it is 'read' – also play a role ...

User comments : 0